US equities |
SPCX $166.41 ▲+4.69% NVDA $236.84 ▲+1.23% MU $1,064.48 ▼-0.97% TSLA $377.43 ▲+1.85% MSFT $526.27 ▲+1.69% SNDK $1,712.00 ▼-0.46% INTC $117.25 ▼-1.74% META $745.49 ▲+2.39%
FinancialContent

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0012 UNCHANGED
Last Price Updated: 3:34 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESS Newswire
News headline image
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Via ACCESSWIRE
News headline image
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Via ACCESSWIRE
News headline image
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Via ACCESSWIRE
News headline image
Lexaria Forms New Scientific Advisory Board
Via ACCESSWIRE
News headline image
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Via ACCESSWIRE
News headline image
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Via ACCESSWIRE
News headline image
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Via ACCESSWIRE
News headline image
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Via ACCESSWIRE
News headline image
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Via CannabisNewsWire
Topics Intellectual Property
News headline image
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Via ACCESSWIRE
News headline image
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Via ACCESSWIRE
News headline image
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Via ACCESSWIRE
News headline image
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
News headline image
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
News headline image
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Via ACCESSWIRE
News headline image
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Via ACCESSWIRE
News headline image
Lexaria Welcomes Industry Veteran as New CEO
Via ACCESSWIRE
News headline image
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria Updates Current GLP-1 Market
Via ACCESSWIRE
News headline image
Lexaria Appoints Michael Shankman as Chief Financial Officer
Via ACCESSWIRE
News headline image
First Results from Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Releases Strategic Letter from the Outgoing CEO
Via ACCESSWIRE
News headline image
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Via ACCESSWIRE
News headline image
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 Next >